11/5/2026

speaker
Conference Call Operator
Operator

Hello, everyone, and welcome to Astrona Health's third quarter 2026 earnings call. At this time, all participants are in a listen-only mode. Later, you will have the opportunity to ask questions during the question-and-answer session, and instructions will be provided at that time. Today's speakers will be Brandon Sim, President and Chief Executive Officer of Astrona Health, and Chandan Basho, Chief Operating and Financial Officer. The press release announcing Astrona Health's results for the third quarter ended September 30th, 2026, is available in the investor relations section of the company's website at www.astranahealth.com. The company will discuss certain non-GAAP measures during this call. Reconciliations to the most comparable GAAP measures are included in the press release. To provide some additional background information, On the results, the company has made a supplemental deck available on its website. A replay of this broadcast will be available on Astana Health's website after the conclusion of this call. Before we get started, I would like to remind everyone that this conference call and any accompanying information discussed herein contains certain forward-looking statements within the meanings of the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by such terms as anticipate, believe, expect, future, plan, outlook, and willing conclude, among other things. Statements regarding the company's guidance, continued growth, acquisition strategy, ability to deliver sustainable long-term value, ability to respond to changing environment, liquidity, operational focus, strategic focus, Growth Plans, and Acquisition Integration Efforts. Although the company believes that the expectations reflected in these forward-looking statements are reasonable as of today, those statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected. There could be no assurance that these expectations will prove to be correct. Information about risks, associations, with the investing in Estrana Health is included in the filings with the Securities and Exchange Commission, which we encourage you to review before making any investment decision. The company does not assume any obligation to update any forward-looking statement as a result of new information, future events, change in market conditions, or otherwise, except as required by law. Regarding the disclaimer language, if you would like to refer to slide two of the conference call presentation for further information. With that, I will turn the call over to Astrana Health's President and Chief Executive Officer, Brandon Sim. Please go ahead, Brandon.

speaker
Brandon Sim
President and Chief Executive Officer, Astrana Health

Good afternoon, and thank you for joining us today. Astrana delivered another strong quarter, driven by continued growth, margin expansion, and disciplined execution across the business. Revenue in the third quarter reached a record $1.02 billion, up 7% year-over-year, and adjusted EBITDA was a record $77.2 million, up 13% year-over-year, and near the high end of guidance. Adjusted diluted earnings per share was 71 cents. With prospects now included in both comparison periods, these results provide a clearer view of the underlying earnings power of our combined business. Importantly, our 13% year-over-year adjusted EBITDA growth was driven organically, reflecting the maturation of our risk-bearing cohorts, particularly in Texas, improved medical cost performance across our care partners business, and continued operating efficiencies. Capitation revenue grew 8.5%, despite Medicaid and exchange membership attrition. while adjusted EBITDA grew approximately twice as fast as total revenue, demonstrating the operating leverage and resilience of our business. Free cash flow also remains strong. Through the first nine months of the year, we've generated approximately $105 million in free cash flow and repaid $116 million of debt. This brings net leverage to approximately 2.2 times, well ahead of the leveraging commitments we made when we acquired Prospect. And we remain on track to deliver on our free cash flow guidance for the year. Underlying these results is the differentiated operating platform we have built at Estrana, bringing together three foundational capabilities Intelligence, Alignment, and Delivery. Intelligence is how we leverage our vast clinical and operational data set, together with proprietary models and AI, to identify what care patients need, when they need it, and how to deliver it most effectively. Alignment is how we use our delegated, pair-agnostic model and provider-facing technology platform to align clinical and financial incentives around delivering the right care. And delivery is how we put this into practice using our broad integrated network of physician providers and care teams to translate those insights into action and better outcomes for patients. What makes this platform particularly powerful is the feedback loop between these capabilities. We can identify opportunities to improve care enable physicians to act on them and then measure the resulting clinical outcomes and total cost of care. Those insights then feed back into our platform, continuously improving our recommendations, execution, and underwriting. As this flywheel compounds, we believe we can reduce the upfront investment required to enter new markets, accelerate the path to profitability for new populations, and deliver increasingly consistent and predictable outcomes and economics. Our third quarter results demonstrate the growing impact of our platform. I'll walk through our progress against the four strategic priorities we've consistently focused on. Our first priority is growing membership responsibly. We ended the quarter with approximately 1.5 million members under management. Medicare Advantage membership grew organically at a high single-digit rate year over year, even as many health plans across the industry continue to reduce their Medicare Advantage footprints. This growth was partially offset by Medicaid and Exchange membership attrition, with Medicaid attrition expected to be at the middle to high end of the 10% to 15% range we assumed at the beginning of the year. As we discussed last quarter, our strong operating performance has given us greater flexibility to invest in growth while maintaining our profitability and balance sheet objectives. We continue to reinvest a portion of that outperformance towards attractive new opportunities across markets and business lines while remaining on track to deliver on our full year of financial commitments. And we're seeing those investments translate into tangible progress. On the provider side, we completed a tuck-in acquisition of an independent physician association in Georgia on October 1st, further expanding our presence in the Southeast. We also added two new clients to our AI-powered care enablement platform during the quarter, a leading primary and multi-specialty provider group in Connecticut and a hospital client in California. We expect both to be onboarded onto the Estrana platform by early 2027. On the payer side, we've entered into several new Medicare Advantage partnerships effective January 1st, 2027, building upon our existing networks and geographic expansion efforts. Together, these opportunities demonstrate the breadth of our growth model, spanning risk-bearing populations, physician network expansion, and technology-enabled services. all leveraging our shared platform to drive scalable, capital efficient growth. Our second priority is continuing to progress responsibly into full risk arrangements. We are on track for approximately 82% of our capitation revenue to be generated under full risk arrangements by year end, up from 76% at year end of 2025. Within our care partners business, Approximately 46% of members were in full risk arrangements compared to 34% a year ago. Importantly, the full risk cohorts that we added earlier this year continue to perform in line with or ahead of our underwriting expectations. Texas is a particularly compelling example. Throughout 2026, we transitioned approximately 7,000 Medicare Advantage members from gain share to global risk. and added another 3,000 members under professional risk arrangements through a new payer partnership. Since then, we've onboarded those populations onto Estrana's technology platform and deployed our integrated care model, equipping local physicians and care teams with the clinical insights, care coordination capabilities and operational support to manage patients more effectively. Three quarters in, our Texas business is performing ahead of plan with medical cost trends running favorably to our underwriting assumptions and profitability improving faster than anticipated. This is an important proof point for our ability to enter new markets, assume greater risk responsibly, and improve profitability as cohorts mature. We believe the same operating model can be replicated across additional markets, with Texas becoming an increasingly meaningful contributor over time. Our third priority is managing medical cost trend through better clinical outcomes. Our delegated model enables us to intervene earlier, coordinate care more effectively, and align clinical decision-making with the long-term health of our patients. Year to date, overall medical cost trend remains slightly better than the approximately 5.2% assumption embedded in our full year guidance. Within that, Medicare Advantage and Original Medicare continue to perform favorably relative to our expectations. Medicaid medical cost trend is running above our initial assumptions, while commercial is slightly above expectations, primarily due to clinician administered drug costs. These pressures remain manageable within our diversified portfolio, and our consolidated medical cost performance continues to outperform our expectations at the beginning of the year. Underpinning our approach is our growing suite of technology enabled clinical programs. Our annual wellness visit program has reached nearly 65% of eligible members so far this year, helping identify risks earlier and close gaps in care. We also continue to advance our disease management programs for high risk conditions, including congestive heart failure, COPD, and chronic kidney disease. alongside our care at home capabilities. These programs, together with our annual wellness visit program, run on our proprietary care management platform, Pathways, enabling us to coordinate interventions and standardize care across markets. By building these capabilities directly into our own technology platform, we are creating a repeatable clinical operating model that can deliver consistent, high quality care as we expand across physicians, populations and geographies. Our fourth priority is continuing to expand operating leverage as we scale. Last quarter, we highlighted how AI-powered workflows in claims operations and referral management reduced handling times by more than 50%. Since then, we've continued advancing beyond individual task automation towards automating entire business processes. One example is in claims administration, where we're building an AI orchestrated process that translates the economic terms of a provider contract directly into accurate claims configuration and payment. Historically, these contracts required hours of manual work to process. Our newest AI agents are reducing that process from hours to minutes while improving accuracy. And importantly, All of these capabilities are being built into our own operating platform, allowing us to deploy them across our network and capture the benefits as we scale. On the provider side, just this week, we launched Atlas, the next generation of our provider-facing platform. Atlas helps physicians prioritize patients who need attention most, identify gaps in care, and respond to high-risk events in real time, directly within their existing workflows. These applications are built on shared infrastructure, allowing us to deploy new capabilities across markets and business lines without rebuilding them independently. We're seeing the improvements to our platform continue to translate into tangible operating leverage. Year-to-date G&A has declined to approximately 6.2% of revenue, an improvement of approximately 80 basis points year-over-year even as we continue investing in growth and new capabilities. We expect full-year G&A to remain around this level with meaningful opportunity for further operating leverage over the medium term as our AI capabilities mature and as we continue to scale. Turning briefly to prospect, more than a year after closing the transaction, performance continues to validate our original investment thesis. Gross provider retention remained above 99%. Operating expense synergies are at the high end of our original annual target of 12 to 15 million. An aggregate medical cost trend across the legacy prospect business remains below our underwriting assumptions. Just as importantly, the operational transformation has taken hold. We're consolidating legacy prospect payer arrangements into our enterprise contracts with shared health plan partners. Our California growth efforts now operate through a unified team and pipeline, and legacy prospect physicians are increasingly integrated into this strana care model. As a result, we now view and manage prospect as part of our core business rather than as a separate integration initiative going forward. Turning now to initial thoughts about 2027. In Medicare Advantage, the annual enrollment period is underway. We expect our weighted average paid star rating to improve modestly in 2027 versus 2026 and remain relatively stable in 2028. With our membership diversified across more than a dozen health plans, our exposure to any individual contract remains limited. Regarding the 2027 Medicare Advantage final rate notice, we continue to believe that we face immaterial impact from the exclusion of certain diagnosis sources. and we expect Medicare Advantage margins to remain stable into 2027. In Medicaid, we continue to plan conservatively for changes in 2027, including the transition of UIS members to fee for service, work requirements, more frequent eligibility redeterminations and changes to asset limits. We are working closely with our health plan partners and our community to manage these transitions and support continuity of care for our members. We've been incorporating these developments into our planning for some time and currently anticipate a 10% to 15% decline in Medicaid membership in 2027. In the exchange business, membership attrition has been more favorable than our original assumption of a 30% to 40% decline this year, and the business remains approximately 3% of revenue. Commercial membership also remains stable. Stepping back, We entered 2027 with several meaningful growth drivers. A continued maturation of new cohorts in core and expansion markets, additional full risk conversions, new Medicare Advantage payer partnerships, and continued operating leverage from our platform. These opportunities are balanced against the membership changes we've discussed in Medicaid and Exchange, all of which will be reflected in our formal 2027 guidance. In all, we remain confident in our ability to deliver at least mid-teens annual adjusted EBITDA growth over the medium term. We believe we're still in the early innings of realizing the full potential of the platform we've built. At its core, Estrana's long-term opportunity is not defined by any single payer, program, or reimbursement model. We are a physician-centric company that uses technology to help doctors deliver better, more consistent care at a lower total cost. That value proposition extends across Medicare Advantage, Original Medicare, Medicaid, and commercial populations. And regardless of how healthcare policy and reimbursement evolve, improving quality, expanding access, and managing healthcare costs will remain fundamental national priorities. and we believe Estrana is uniquely positioned to help address them. As we scale our platform nationally, we see a significant opportunity to improve outcomes for more Americans while delivering increasingly predictable and attractive economics for our business. With that, I'll turn the call over to Chan to review our financial results and outlook in more detail.

speaker
Chandan Bhardwaj
Chief Operating Officer and Chief Financial Officer, Astrana Health

Thank you, Brandon. and good afternoon everyone. Our third quarter results demonstrate continued financial and operating discipline. Adjusted EBITDA was at the high end of our guidance range. We generated strong year-to-date free cash flow and we continued reducing leverage. Our performance puts us in a strong position entering the fourth quarter. We are maintaining the midpoint of our full-year adjusted EBITDA outlook while continuing to invest in pair relationships, recently converted risk cohorts, new care enablement clients, and geographic expansion opportunities that we expect to contribute to growth beyond 2026. Today, I'll review our third quarter financial results Cashflow and Balance Sheet, the evolving revenue presentation of our ACO business, and our updated outlook for the year. Total revenue for the third quarter was $1.02 billion, up 7% versus the prior year period. With prospect included in both comparison periods for the first time, these results provide a clearer view of the underlying performance of our combined business. Revenue growth was driven by the continued ramp of full-risk contracts, including conversions in California and Texas, organic Medicare Advantage membership growth, and Medicaid members transitioned to us during the quarter. These contributions were partially offset by Medicaid and exchange membership attrition. Adjusted EBITDA for the quarter was $77.2 million. Up 13% versus the prior year period and at the high end of our guidance range of $72.5 to $77.5 million. This reflects strong performance in Texas, favorable results in our original Medicare business, and continued improvement in our care partners' medical cost ratio. Net income attributable to Estrana was $13 million and adjusted diluted EPS was $0.71. G&A was 6.6% of revenue in the quarter and 6.2% year to date, reflecting continued operating discipline as we scale the business and invest in new capabilities. Turning to cash flow, we generated approximately $105 million in free cash flow through the first nine months of the year. As we noted last year, cash flow in the second half of the year is seasonally lighter, as a portion of our first half cash flow reflected the timing of ACO settlement receipts. We remain on track to deliver full-year free cash flow within our guidance range of $107.5 million to $130 million. On the balance sheet, we repaid approximately $12 million of debt during the quarter, bringing year-to-date debt reduction to approximately $116 million. We ended the quarter with $396 million in cash and $581 million of net debt. Trailing 12 months gross leverage declined to 3.7 times, down from a pro forma LTM gross leverage of 4.4 times in the prior year period. Net leverage declined to 2.2 times on a trailing 12-month basis, down from a pro forma LTM net leverage of 2.5 times in the prior year period. We remain on track to approach two times net leverage by year end, well ahead of the deleveraging trajectory we originally outlined following the prospect acquisition. Separately, we continue to make progress on remediating the material weakness we disclosed previously. The work remains on schedule and we are currently expecting to complete our assessment by year end. Turning briefly to our ACO business. With the ACO REACH model concluding at the end of 2026, we're preparing for CMS's transition to its new lead model in 2027. We remain disciplined in our approach to ACO programs, prioritizing opportunities where we believe our clinical and operating model can consistently deliver strong outcomes and attractive economics. I want to spend a moment on how these programs show up in our reported revenue because the accounting differs by program. Under ACO REACH, we recognize the full Medicare benchmark as revenue with the associated medical costs in our expenses. We expect LEED to be treated in the same manner. Under MSSP, we recognize only our share of the savings on a net basis. As a result, as our ACO program mix evolves, changes in our reported gap revenue won't reflect necessarily changes in the total Medicare spend we're managing or in our opportunity to generate shared savings. Importantly, our focus remains on the underlying economics of these programs rather than how revenue is presented. We believe our clinical and operating capabilities position us to continue generating attractive shared savings as the accountable care landscape evolves. To provide investors with a more consistent view of the scale of our business across programs, we're introducing a supplemental measure Gross Equivalent Consolidated Premiums or premiums at risk. It represents our MSSP populations on the same gross basis as ACO REACH by including their full Medicare expenditure benchmarks rather than only the net revenue recognized under GAAP. On this basis, we expect approximately 4.45 billion in premiums at risk for 2026 compared to our reported revenue guidance of 3.9 billion to 4 billion. The difference reflects the MSSP benchmarks that weren't included in GAAP revenue. We'll provide additional details on the anticipated financial impact of any ACO program transitions when we issue formal 2027 guidance with our fourth quarter results. Finally, turning to our full year outlook. We're narrowing our full-year guidance ranges for revenue, adjusted EBITDA, and free cash flow while maintaining the midpoint of each. We now expect revenue of $3.9 billion to $4 billion, adjusted EBITDA of $261 million to $274 million, and free cash flow of $107.5 million to $130 million. These updates reflect greater visibility in our full-year performance with one quarter remaining. Our outlook continues to assume conservative Medicaid membership trends and no contribution from HQAF 10. Importantly, our adjusted EBITDA outlook remains above our original expectations for the year, even as we are deliberately reinvesting a portion of our operating outperformance into new payer relationships, risk cohorts, care enablement expansion, and geographic growth opportunities. We believe this demonstrates our ability to deliver on our financial commitments while investing in the next phase of growth. For the fourth quarter, we expect revenue between $939 million and $1.04 billion and adjusted EBITDA between $48.5 and $61.5 million. Consistent with prior years, we expect the fourth quarter to be our lowest quarter of the year in terms of profitability. Our third quarter results included recognition of MSSP shared savings and final Medicare Advantage risk adjustment sweeps, which are not expected to recur in the fourth quarter. Our fourth quarter outlook also incorporates continued Medicaid membership attrition and investments associated with onboarding new pair contracts and other growth opportunities. We will provide formal 2027 guidance with our fourth quarter results. Taken together, our record revenue and quarterly adjusted EBITDA, strong free cash flow generation and continued deleveraging reinforce our confidence in the trajectory of our business. We enter 2027 with a stronger balance sheet, a growing base of profitable risk-bearing populations, and the financial flexibility to continue investing in our long-term growth opportunities. With that, operator, we're happy to take questions.

Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.

Disclaimer

This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

-

-

Use this data in your own app

Pull this call's transcript, audio and slides with the Earnings call transcripts API.

See pricing

9,000+ companies · REST API